Adding a statement that an overhaul of its OTC drug monograph program didn’t affect the US Food and Drug Administration’s oversight of homeopathic drugs is the biggest change between the agency’s draft and final guidances on regulating the Rx and OTC products.
No Change To US FDA’s Risk-Based Homeopathic Enforcement From Its OTC Monograph Overhaul
Final guidance presents same descriptions of six "categories of homeopathic drug products ... potentially posing higher risks to public health” agency stated in 2019 revised draft. Agency adds reference to monograph reform in explanation of how homeopathics aren't GRASE.

More from Regulation
More from Policy & Regulation
AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.
The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.
An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.